
U.S. pharmaceutical companies have strongly criticized Australia's AU$18 billion Pharmaceutical Benefits Scheme (PBS), calling for President Donald Trump to impose punitive tariffs on the country.
The pharmaceutical industry argues that PBS, which subsidizes medicines for millions of Australians, has hurt American exports and devalued U.S. innovations in medicine, the Sydney Morning Herald reported.